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Abstract 
Background: Behçet’s disease is a rare, multisystem vasculitis disease characterized by 
recurrent orogenital ulcerations with its etiology remained unclear. The transcription factor p53 
has been reported to be upregulated in some autoimmune diseases, such as lupus 
erythematosus, dermatomyositis, and psoriasis. However, little is known about its alteration in 
Behçet’s disease. 
Methods: Keratinocyte cultures of both skin and oral origins were treated sera of 18 Behcet 
patients for 24 hours and analyzed by indirect immunofluorescence for p53 expression. The 
specificity of p53 expression was confirmed by siRNA mediated p53 knockdown and the serum 
IgG removal studies. The expression of p53 levels was quantitatively analyzed with ImageJ.         
Results: It was shown that the expression of p53 is increased in skin and oral keratinocyte cell 
lines, in both the nucleus and cytoplasm of cells treated with patient sera compared to controls. 
Either p53 knockdown or IgG removal results in a reduction of p53 levels relative to cells treated 
with patient sera without p53 knockdown or IgG depletion.  
Conclusions: This in vitro study provides the first evidence that Behçet’s disease sera can 
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1. Introduction
Behçet’s disease (BD) is a rare, multisystem vasculitis disease of unknown cause and is 
characterized by recurrent orogenital ulcerations, skin lesions, musculoskeletal, gastrointestinal, 
ophthalmic, neurological and vascular involvement (1;2). It is thought that certain infectious 
factors (in particular Streptococcus Sanguis) can trigger the symptoms in genetically 
predisposed individuals (3). Some studies suggest that patients with BD were more susceptible 
to develop cancer, however, other studies report its association with lower incidence of cancer 
thus the association of BD with cancer is still a controversial issue (4;5). Currently, no curative 
solutions are available in the clinical treatment of BD. Nevertheless, treatment of BD aims to 
relieve symptoms, reduce tissue damage, resolve inflammation, eliminate recurrence and 
prevent life-threatening conditions (6). There continues to be an interest in trying to understand 
the underlying etiopathogenesis of BD. 
p53 is a transcription factor predominantly located in the nucleus that regulates a host of 
molecular functions (review by Karen or someone similar). In response to stress signals such as 
DNA damage and various cellular insults, p53 is activated with an increased expression which in 
turn triggers different biological outputs, such as cell-cycle arrest, programmed cell death 
(apoptosis), modulation of autophagy or senescence (7;8). Overexpression of p53 has been 
reported in various diseases such as rheumatoid arthritis (RA) (9), discoid lupus erythematosus 
(DLE) (10), psoriasis (11), cutaneous lupus erythematosus (CLE) and dermatomyositis (12;13). 
However so far, little is known about the alteration of p53 in BD. Our recent study has shown 
that treatment of keratinocyte cell cultures with patient sera from pemphigus vulgaris (PV), an 
autoimmune blistering disease, evokes elevated p53 expression levels (14). Here in this present 
study, we investigated whether BD patient sera are capable of inducing enhanced p53 
expression in keratinocyte cultures. Our results generated from this in vitro study indicate on 
exposure to BD sera there is induction of p53 in keratinocytes derived from both the skin and 
oral mucosa. This novel finding reveals important information on BD pathogenesis that could 
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2. Materials and Methods
2.1 Cell lines and BD sera samples
Two different cell lines, i.e. NTERT immortalized skin keratinocytes and oral keratinocytes 
OKF6/TERT1 derived from floor of mouth, were used in this study and both are known to 
express wild type p53 (15). Cells were maintained in keratinocytes serum-free medium (KSFM) 
(17005402, Thermo Scientific) routinely and were grown in keratinocyte growth medium (KGM) 
containing three parts of DMEM Dulbecco’s Modified Eagle Medium (DMEM) (12-604F, Lonza), 
one part of Ham’s F12 medium (Lonza), 10% FCS, 0.4 µg/ml hydrocortisone, 5 µg/ml insulin and 
1% penicillin-streptomycin for experiment with BD sera treatment. They were kept at 37°C in a 
humidified atmosphere of 5% CO2./95% air Normal control human serum was purchased 
(Sigma) and 18 sera from BD patients obtained from the London Behcet’s Centre fully 
characterized (Table 1) with informed patient consent and ethical approval (Committee and 
reference number). The sera samples were preserved at -20 °C and were used to treat NTERT 
and OKF6/TERT1 cells, respectively. All sera were diluted in KGM at 40% except for the serum 
dosage experiments.
2.2 Antibodies
p53 mAb (DO-1) (ab1101, Abcam) and Alexa fluor 488 goat anti-mouse IgG were used, all in 
1/150 dilution.
2.3 Immunofluorescence (IMF) staining 
The general IMF staining procedures were followed throughout experiments to stain cells grown 
on coverslips in 24-well plates. At least five images were taken in the arbitrary regions for each 
sample and saved for image analysis later. All images were processed and analyzed with 
ImageJ, which is a Java-based image processing program developed by National Institutes of 
health. 
2.4 siRNA transfection
The transfection procedures followed the protocol provided with DharmaFECT reagent (14). For 
p53 siRNA transfection, 2 × 105 cells were seeded in 6-well plate per well and were allowed to 
grow for 24 hours before transfection in OPTIMEM 1 (Thermo Scientific). The scrambled control 
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incubated for 10 minutes before adding into the culture medium at the final concentration of 80 
nM. After 24 hours, cells were harvested and plated on coverslips in KSFM medium. Then, the 
medium was replaced with KGM and cells were allowed to grow overnight. The next day, the 
sera samples were prepared at 40% in KGM as described above before being added into each 
well and incubated for 24 hours prior to fixation and IMF staining.
2.5 IgG depletion
This experiment was performed twice. First, 100μl of Protein G Sepharose (ab193259) supplied 
as 50% slurry and 20% Ethanol was used for the IgG depletion from normal control and BD sera 
samples, respectively. In the second attempt, a similar protocol was performed using 200 μl of 
Protein G Sepharose.
3. Results
3.1 Enhanced p53 expression by BD sera in keratinocyte cultures
The first goal of this study was to determine whether the expression of p53 is increased in 
keratinocyte cultures treated with BD patient sera and this was performed in the NTERT cell line 
harboring wild type p53. Cells were seeded on coverslips in 24-well plate at confluent density for 
1 day before being treated BD sera, alongside with control sera from normal healthy individuals, 
at the 40% concentration diluted in keratinocyte growth medium (KGM) and cells were fixed 24 
hours later and were proceeded for indirect immunostaining for p53 with a mouse monoclonal 
antibody. In total, 16 patient serum samples were investigated compared to two normal control 
sera and pooled data in this analysis was shown in Figure 1. Enhanced p53 in both the nucleus 
and cytoplasm was indicated in cells treated with BD sera compared to control serum treated 
samples (p<0.0001, Figure 1A,B). The specificity of p53 expression and staining by the mouse 
monoclonal antibody was demonstrated by p53 specific knockdown with transient RNAi 
transfection with a marked decrease in the p53 staining by immunofluorescence (IMF) (p<0.01, 
Figure 1C). Some BD serum treated cells exhibited drastic morphological changes with 
remarkable p53 expression in both the nucleus and cytoplasm, suggesting some cytotoxic effect 
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3.2 Enhanced p53 expression 
Next, a dose-dependent experiment was performed with BD sera and in this case, cells were 
treated with a couple of BD serum samples at the final concentrations of 10% and 30%, 
respectively, alongside the normal control serum treated with cells as well as the cells without 
addition of sera. These results indicated a dose-dependent augmentation of p53 expression, 
though with some variations according to the individual serum samples (Figure 2). For instance, 
BD1772 exhibited an approximately 10-fold increase in p53 expression levels than BD3374 in a 
dose-dependent manner, with the latter showed no augmented p53 expression at all at the 10% 
concentration compared to the respected control (p>0.05, Figure 2). These data suggest further 
a specific effect in p53 elevation induced by BD sera. Interestingly, enhanced p53 levels also 
were associated with the addition of sera in the culture media regardless of disease condition 
(Figure 2).         
3.3 Induction of p53 by BD sera was also detected in oral keratinocyte cells
BD patients primarily present ulcerations in the oral mucous membrane. We asked whether the 
same effect in the p53 induction also is detectable in oral keratinocytes with exposure to BD 
sera. To address this question, we treated an immortal oral keratinocyte line OKF6/TERT1 
derived from the floor of mouth (gift from James Rheinwald (15)). Cells were seeded at the same 
densities and treated with BD and normal control sera at the 40% concentration for 24 hours, as 
described above, prior to IMF for p53. Ten BD serum samples were used to treat the 
OKF6/TERT1 cells alongside normal healthy control sera, however, seven of BD samples 
caused somewhat different morphology in OKF6/TERT1 cells, with diffuse p53 staining coupled 
with enlarged cell size (low panels Figure 3). Some of these cells exhibited condensed nuclear 
DAPI staining and concomitantly the faint p53 staining (arrows in Figure 3), whereas others 
showed the loss of nuclear staining by DAPI (arrowheads in Figure 3), suggesting cells had 
undergone programmed cell death or apoptosis. The other three BD serum treated cells 
displayed similar changes with elevated p53 expression as observed in NTERT cells and also 
showed a dose-dependent response in p53 expression (Figure 3A,C). 
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Finally, we asked whether the induction of p53 by BD sera was primarily caused by IgG and to 
address this question, we depleted IgG with protein G prior to treating the NTERT cells 
alongside with control sera. Four BD sera samples were tested in this regard and showed a 
significant reduction of p53 in both the nucleus and cytoplasm, in particular in cells with a greater 
concentration of BD serum sample, i.e. 40%, compared to controls (p<0.001, Figure 4). These 
data suggest that the BD sera induced p53 expression is likely associated with IgGs existing in 
the patient sera. 
4. Discussion
BD with unknown etiology is a disease affecting several organs but oral and genital ulcers are 
regarded as a hallmark of the disease and the first signs in most of the cases (16). 
Overexpression of p53 has been reported in some diseases such as in the synovium of RA (9), 
in the lesion skins of psoriasis (11) and the patients with DLE, CLE, and Dermatomyositis 
(10;13). Thus, the enhanced p53 expression seems to be associated with pathogenesis of 
several diseases. This study aimed to determine whether BD sera is capable of inducing p53 
expression and thus, we performed IMF analysis for p53 expression in keratinocyte cultures 
treated with BD sera from a cohort of 18 patients with BD. Both skin-derived NTERT and oral-
derived OKF6/TERT1 keratinocyte cell lines were used in the study. The levels of p53 
expression and subcellular distribution in keratinocytes treated with control and BD sera for 24 
hours were analyzed by IMF combined with quantitative image process. A significant increase of 
p53 was detected in cells treated with BD sera compared to controls, especially in nuclear p53, 
suggesting activation of p53. Similar findings were observed in both NTERT and OKF6/TERT1 
keratinocyte cell lines. Nevertheless, the OKF6/TERT1 cells seemed to be more sensitive and 
showed drastic morphological changes in response to some BD sera samples with nuclear 
condensation or the loss of DAPI staining (e.g. BD2327, Figure 3A). Some BD sera induced the 
augmented p53 in both the nuclear and cytoplasmic, whereas others caused only pronounced 
cytoplasmic p53 expression. The effect of BD sera on p53 induction was demonstrated in a 
dose-dependent manner in both NTERT and OKF6/TERT1 cells. In addition, the specificity of 
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staining signals induced by sera (Figure 1C) in both control and BD serum treated cells, 
especially the cytoplasmic p53 in cells treated with BD sera. Enrichment of the p53 pathway has 
been reported in the peripheral blood cells of BD using the microRNA microarray analysis (17). 
Furthermore, an upregulation of the apoptotic genes, for example, BCL2-related, MCL-1, and 
BCL2L11 were found in the peripheral blood cells of BD patients in a study of gene expression 
profiling (18).
Finally, to address the effect of sera IgG on p53 induction, we removed IgG from BD and control 
sera by using protein G prior to treating the cells alongside the matched sera control without IgG 
depletion, and showed that IgG-depletion from BD sera resulted in a significant decrease of p53 
expression compared with the matched BD sera without IgG removal, suggesting that IgG is 
likely responsible, at least in part, for the p53 induction in cells treated with patient sera. 
The increased p53 expression in keratinocytes with BD sera exposure could be due to the high 
levels of inflammation in BD which triggers the induction of p53 or due to the monoclonal 
antibody drugs used in the treatment of BD. It has been reported that infliximab can cause 
induction of p53 (19;20). A study conducted by Mitoma et al. reported the role of infliximab in the 
upregulation of proteins, such as Bax, Bak, and p21WAF1/CIP1, suggesting the activation of the p53 
pathway (20). Overexpression of p53 was also found in psoriatic keratinocytes in patients 
treated with infliximab (19;21). In this present study, some clinical information was obtained, for 
example, the BD 3374 sera sample showed induction of p53, however, the patient was not 
under any drug treatment but had folliculitis at the time of taking the sample (Table 1). Thus, it 
would be necessary to evaluate the sera of patients with and without infliximab treatment.
In summary, this study provides the first evidence that BD sera are able to provoke p53 
expression in keratinocyte cultures, in a dose-dependent manner, suggesting some pathological 
factors existing in the patient sera. In addition, the study suggests that the sera IgG could be a 
potential contributing factor in the induction of p53. These findings may have implications in the 
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Figure Legends
Figure 1. Indirect immunofluorescence for p53 staining in NTERT cells treated with BD patient 
sera. (A) The representative images of p53 staining in NTERTs treated with healthy control 
(Norm Ct) or BD sera at the final concentration of 40% in keratinocyte growth medium for 24 
hours. The insert was the technical negative control with the secondary antibody alone (Neg Ct). 
(B) Quantitation analysis of all samples indicated a significant increase of p53 expression, 
including both the nuclear (white asterisks) and cytoplasmic (black asterisk) p53 levels, in cells 
treated with BD sera compared to controls (16 BD cases included). (C) p53 knockdown almost 
completely abrogated the p53 signals by IMF (n=2). The same effect was also seen with BD 
sera (data not shown. (5 arbitrary fields per BD serum treated cells were analyzed to generate 
the mean value for each sample, two-tailed, unequal distribution Student’s t-test was used to 
obtain the p values for comparison between the samples, *p<0.05;**p<0.01;****p < 0.0001).
Figure 2. Dose-dependent response in p53 expression in NTERT cells treated with normal 
control and BD sera, respectively. Top panels showed an example of p53 expression and its 
subcellular distribution in the cellular response to BD patient sera at 10% and 30% 
concentrations, respectively, alongside controls with normal sera or no addition of sera. Lower 
panels were the results of another example with BD sera that showed a more drastic effect in 
p53 expression, in particular in cells treated with 30% BD serum. The data were representative 
of at least two independent experiments. Grey asterisks were comparisons for cytoplasmic p53 
between the samples and black asterisks were for the nuclear p53 comparisons between the 
samples. (n=5, two-tailed Student’s t-test, **p <0.01;***p<0.001;****p < 0.0001).
Figure 3. Indirect immunofluorescence of p53 in oral keratinocyte OKF6/TERT1 cells treated 
with BD patient sera. (A) The representative images of p53 staining in cells treated with normal 
control (Norm Ct) and BD sera at a final concentration of 40% for 24 hours. Note that different 
p53 staining patterns and cell morphology were shown in cells treated with BD sera. Arrows 
indicated cells with low p53 expression whereas arrowheads indicated cells with negative DAPI 
nuclear staining in the absence or presence of p53 expression. (B) Quantitation of all samples 
(10 BD sera samples were included). (C) Dose-dependent augmentation of p53 expression and 
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alongside control sera. Grey asterisks were comparisons for cytoplasmic p53 between the 
samples. (n=5 fields per sample, *p<0.05; **p<0.01). 
Figure 4. IgG removal from sera results in a reduction of p53 expression in both nucleus and 
cytoplasm in cells treated with BD sera, especially at the 40% serum concentration. NTERT cells 
were treated with BD sera with and without IgG depletion, at 40% (top panels) and 30% (lower 
panels) concentrations, respectively. A significant decrease in p53 expression levels was shown 
in cells treated with BD3374 at 40% (top panels) compared to controls. Data were a 











Table 1. Patient characteristics used in the study
Patient Sample ID Age Gender Orogenital ulcerations
Patient-1 3726 42 Female Yes
Patient-2 1772 25 Female Yes
Patient-3 3374 35 Female No 
Patient-4 2327 27 Male N/A
Patient-5 5388 25 Female Yes
Patient-6 399 56 Male No 
Patient-7 639 39 Male Yes (oral ulcers)
Patient-8 467 27 Male No 
Patient-9 1325 21 Female No 
Patient-10 6702 48 Male N/A
Patient-11 8720 40 Female Yes (oral ulcers)
Patient-12 5639 22 Female Yes (oral ulcers)
Patient-13 379 23 Male Yes (minimal oral ulceration)
Patient-14 8687 NA Male Yes (minimal oral ulceration)
Patient-15 1560 33 Male Yes 
Patient-16 3583 48 Male No
Patient-17 4218 18 Male No
Patient-18 391 23 Female No
IgG depletion
-
Yes
Yes 
-
-
-
-
-
-
Yes 
Yes
-
-
-
-
-
-
-




